INBS · Intelligent Bio Solutions Inc.
AI read · Neutral
The AI's read
INBS announced recertification to ISO 13485:2016 and ISO 9001:2015, aligning its quality framework with the FDA's updated QMS rules. That alignment directly supports its push for FDA clearance of a non-invasive fingerprint sweat drug test. The market reacted immediately, with the stock up roughly 20% and RSI near 75, so a large part of the rally looks priced in. Volume and a tight cap mean this can reverse quickly on any fade in sentiment. Our take is neutral. The news is constructive for regulatory optics, but the pop, stretched technicals, and choppy market regime lower asymmetric upside right now, so we prefer waiting for clearer FDA timing or a pullback.